Contents

Search

Prevail trial

Study characteristics: - 1700 men with metastatic prostate cancer who had received androgen-deprivation therapy but not chemotherapy - randomized controlled study Treatment: - daily enzalutamide (an androgen-receptor antagonist) vs placebo. Results: - at 12 months, radiographic progression-free survival was higher in the enzalutamide group (65% vs 14%)

General

clinical trial

References

  1. Beer TM et al Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. N Engl J Med. June 1, 2014 PMID: 24881730 http://www.nejm.org/doi/full/10.1056/NEJMoa1405095